What Is Osimertinib and What Is It Used For?

Osimertinib is a third-generation, irreversible EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor classified as an antineoplastic agent. It is indicated exclusively for adult patients aged 18 years and older with non-small cell lung cancer (NSCLC) harbouring EGFR exon 19 deletions or exon 21 (L858R) substitution mutations — confirmed by an approved diagnostic test prior to initiating therapy.

Multiple clinical treatment settings are currently approved for osimertinib:

• Adjuvant treatment of NSCLC following tumour resection in adults aged 18 and older
• First-line treatment of metastatic NSCLC with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations
• Previously treated EGFR T790M mutation-positive metastatic NSCLC
• Locally advanced unresectable stage III NSCLC with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations
• First-line treatment of metastatic EGFR-mutated (exon 19 deletions or exon 21 L858R mutations) NSCLC in combination with pemetrexed and platinum-based chemotherapy

Its role across multiple lines of therapy — from early-stage adjuvant use to advanced metastatic settings — makes osimertinib a cornerstone of targeted oncology treatment. For procurement teams and healthcare providers, understanding the breadth of approved indications is essential for formulary planning and patient access.

How Osimertinib Works: Mechanism of Action

Osimertinib exerts its antitumour effect through irreversible inhibition of mutant forms of the EGFR receptor. Specifically, it binds to the T790M resistance mutation, the L858R activating mutation, and EGFR exon 19 deletion variants at approximately 9-fold lower concentrations than are required to inhibit wild-type EGFR. This selectivity profile is clinically significant: it allows osimertinib to suppress tumour-driving EGFR signalling while reducing the extent of wild-type EGFR suppression compared with earlier-generation inhibitors.

This targeted mechanism aligns with the broader principles of targeted therapy in cancer treatment, where precision inhibition of oncogenic drivers forms the basis of therapeutic strategy. For oncology procurement professionals, understanding this mechanism supports informed decisions around formulary inclusion and clinical pathway alignment.

Approved Indications: EGFR-Mutant NSCLC Treatment Settings

Osimertinib addresses NSCLC across a broad spectrum of clinical settings, all requiring confirmed EGFR mutation status prior to treatment initiation. The five approved indications cover distinct patient populations and lines of therapy:

1. Adjuvant post-resection treatment: Osimertinib is approved for adult patients (aged 18 and older) as adjuvant therapy following complete tumour resection in NSCLC harbouring EGFR exon 19 deletions or exon 21 (L858R) substitution mutations. This represents a significant advance in early-stage disease management.
2. First-line metastatic NSCLC: For adults aged 18 and older with previously untreated metastatic NSCLC carrying EGFR exon 19 deletions or L858R mutations, osimertinib is approved as monotherapy in the first-line setting.
3. T790M mutation-positive previously treated NSCLC: Patients who have progressed on prior EGFR-targeted therapy and whose tumours harbour the T790M resistance mutation are eligible for osimertinib treatment.
4. Locally advanced unresectable stage III NSCLC: Osimertinib is approved for adult patients with locally advanced, unresectable stage III NSCLC with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.
5. First-line combination with pemetrexed and platinum chemotherapy: Osimertinib may also be used in combination with pemetrexed and platinum-based chemotherapy as a first-line treatment for metastatic NSCLC.

EGFR mutation testing is a prerequisite across all indications. Procurement teams supplying oncology centres should ensure that diagnostic infrastructure aligns with therapeutic availability.

Available Brands Sourced from Bangladeshi Manufacturers

We supply six osimertinib tablet brands, all sourced directly from Bangladeshi pharmaceutical manufacturers. Each brand is available in both approved tablet strengths — 40 mg and 80 mg — providing flexibility for clinical use across different patient management scenarios. The osimertinib 80 mg tablet (tab osimertinib 80 mg) is widely referenced in oncology procurement, and all six brands meet this formulation requirement.

The available brands and their respective manufacturers are as follows:

• Osimatab (Eskayef Pharmaceuticals Ltd.) — available as 40 mg and 80 mg tablets
• Osikin (Ziska Pharmaceuticals Ltd.) — available as 40 mg and 80 mg tablets
• Tagrix (Beacon Pharmaceuticals Ltd.) — available as 40 mg and 80 mg tablets
• Osinib (Drug International Ltd.) — available as 40 mg and 80 mg tablets
• Osicent (Incepta Pharmaceuticals Ltd.) — available as 40 mg and 80 mg tablets; Osicent 80 mg is among the most frequently requested presentations
• Osimert (Everest Pharmaceutical Ltd.) — available as 40 mg and 80 mg tablets

All brands listed above are manufactured within Bangladesh and supplied directly from local production facilities. This domestic sourcing model ensures supply chain integrity and supports timely availability for hospitals, oncology centres, and pharmacies operating in the Bangladeshi market.

Procurement buyers based in India and Pakistan are also welcome to inquire about cross-border availability. Our team can advise on supply arrangements and logistics for these markets upon request.

Regulatory Status and DGDA Oversight in Bangladesh

In Bangladesh, all pharmaceutical products containing osimertinib — including Osimatab, Osikin, Tagrix, Osinib, Osicent, and Osimert — are subject to regulatory oversight by the Directorate General of Drug Administration (DGDA), the national medicines authority operating under the Ministry of Health and Family Welfare. The DGDA is responsible for product registration, quality standards, and market authorisation for all pharmaceutical products distributed within Bangladesh. Further information on regulatory requirements is available at dgda.gov.bd.

All regulatory compliance decisions for procurement and dispensing within Bangladesh should be made in accordance with current DGDA guidelines and applicable national pharmaceutical law.

Safety Information: Side Effects and Key Precautions

Healthcare providers and procurement teams should be familiar with the established safety profile of osimertinib. All clinical management decisions must be directed by the treating physician in accordance with the official prescribing information.

Serious adverse reactions requiring prompt clinical attention include:

• Interstitial lung disease (ILD) / Pneumonitis: If ILD or pneumonitis is confirmed, osimertinib therapy must be permanently discontinued.
• QTc interval prolongation: If the QTc interval exceeds 500 milliseconds on at least two separate ECG assessments, therapy must be withheld. Resumption and any dose adjustment are determined by the treating physician per prescribing information.
• Cardiomyopathy: Cardiac function should be monitored as clinically indicated.
• Keratitis: Patients reporting ocular symptoms should be evaluated promptly.
• Embryo-fetal toxicity: Osimertinib can cause fetal harm. Appropriate contraceptive counselling is required.

Lactation: Breastfeeding is not recommended during osimertinib treatment.

How to Inquire About Osimertinib Supply

We supply osimertinib tablets — including Osimatab, Osikin, Tagrix, Osinib, Osicent, and Osimert — sourced directly from Bangladeshi manufacturers to hospitals, oncology centres, retail and institutional pharmacies, and healthcare procurement teams across Bangladesh. All brands are available in both 40 mg and 80 mg tablet strengths.

To inquire about product availability, stock levels, or to place a bulk or single-unit order, please contact our procurement team directly. We do not publish pricing on this platform; all pricing information is provided upon direct inquiry based on order volume and delivery requirements.

Procurement buyers in India and Pakistan are equally welcome to reach out regarding availability and cross-border supply arrangements. Our team is experienced in facilitating pharmaceutical sourcing from Bangladeshi manufacturers to buyers across the region.

For oncology procurement professionals seeking reliable, manufacturer-direct supply of osimertinib tablets in Bangladesh, we encourage you to learn more about how we support cancer patient access through our supply network. Contact us today to discuss your requirements and confirm current availability.